A5012138007- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Cardiovascular and Diving-Related Complications
- Hepatitis C virus research
- Pharmaceutical Economics and Policy
- Bone health and osteoporosis research
- Venous Thromboembolism Diagnosis and Management
- Pharmacovigilance and Adverse Drug Reactions
- Immune Cell Function and Interaction
- Kawasaki Disease and Coronary Complications
- Cerebral Venous Sinus Thrombosis
- Autoimmune and Inflammatory Disorders Research
- Bone and Joint Diseases
- Hip disorders and treatments
- Medication Adherence and Compliance
- Systemic Lupus Erythematosus Research
University of California, San Francisco
2024-2025
Alameda Health System
2022-2023
University of Washington
2018
Racial and ethnic disparities in rheumatoid arthritis (RA) disease activity measures have been documented. We compared racial differences using multiple composite measures, including an objective measure, the multi-biochemical (MBDA) score.Data are derived from University of California, San Francisco RA Cohort, a longitudinal observational cohort. Participants with at least one MBDA measure self-reported race ethnicity were included. Multivariable linear regression evaluated association...
Objective We evaluated the incidence rate and factors associated with fractures among adults ankylosing spondylitis (AS). Methods performed a retrospective cohort study data from Rheumatology Informatics System for Effectiveness registry linked to Medicare claims 2016 2018. Patients were required have two AS International Classification of Diseases codes 30 or more days apart subsequent claim. Then, 1 year baseline characteristics included, after which patients observed fractures. First, we...
Few studies have reported the agreement between medication information derived from ambulatory EHR data compared to administrative claims for high-cost specialty drugs. We used a national EHR-enabled registry, Rheumatology Informatics System Effectiveness (RISE), with linked Medicare in population of patients rheumatoid arthritis (RA) investigate variations different biologic disease-modifying agents (bDMARDs) two sources (RISE vs. claims), categorized by drug, route administration, and...